Vanda Pharmaceuticals Inc. (VNDA) Cash Flow Statement

Operating cash outflows exceeding reported net losses in several quarters suggests that cash consumption is running ahead of accounting losses rather than being masked by non-cash charges. This pattern may indicate working capital drains or operating costs that are not fully captured in the earnings line, and investors should monitor whether the gap narrows as the revenue base grows. The 2025Q4 quarter is an exception, where a $141.2M net loss coincided with only $29.4M of operating outflow, which warrants further investigation into the composition of that charge.

The consistently negative FCF margins, with capital expenditures remaining below 1% of revenue, indicate that the cash burn is driven almost entirely by operating expenses rather than capital investment. The sharp deterioration in 2026Q1 and 2026Q2 followed by partial improvement in 2026Q3 suggests volatility in operating outflows rather than a clear turning point. Absent a sustained shift toward positive operating cash generation, the company appears dependent on its existing liquidity position.

Large swings in working capital relative to the size of quarterly operating outflows suggest that timing of receivables, payables, and accruals is a meaningful driver of reported cash flow. Such volatility makes it difficult to infer underlying cash generation from any single quarter. Investors may wish to examine whether the 2026Q2 inflow reversed in subsequent periods, as that pattern would indicate timing effects rather than structural improvement.

The absence of dividends and repurchases is consistent with a company in an operating cash deficit and does not reflect any capacity for shareholder distributions. The two acquisition outflows in 2026 represent a discretionary use of scarce cash during a period of negative operating cash flow, which may warrant scrutiny of the strategic rationale and expected return. Capital allocation appears oriented toward preserving liquidity rather than returning capital.